XTX Topco Ltd Increases Stock Position in Evolent Health, Inc. (NYSE:EVH)

XTX Topco Ltd boosted its stake in Evolent Health, Inc. (NYSE:EVH) by 122.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,381 shares of the technology company’s stock after purchasing an additional 23,917 shares during the quarter. XTX Topco Ltd’s holdings in Evolent Health were worth $829,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. ICA Group Wealth Management LLC purchased a new stake in Evolent Health in the fourth quarter valued at approximately $33,000. Headlands Technologies LLC purchased a new stake in Evolent Health in the first quarter valued at approximately $46,000. NBC Securities Inc. raised its stake in Evolent Health by 16.6% in the first quarter. NBC Securities Inc. now owns 2,461 shares of the technology company’s stock valued at $81,000 after purchasing an additional 350 shares in the last quarter. Banque Cantonale Vaudoise purchased a new stake in Evolent Health in the first quarter valued at approximately $88,000. Finally, Quest Partners LLC purchased a new stake in Evolent Health in the second quarter valued at approximately $87,000.

Evolent Health Stock Up 0.7 %

Shares of Evolent Health stock opened at $31.04 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.08 and a current ratio of 1.08. Evolent Health, Inc. has a 52-week low of $17.98 and a 52-week high of $35.00. The stock has a market capitalization of $3.61 billion, a price-to-earnings ratio of -24.83 and a beta of 1.57. The company’s 50 day moving average price is $26.67 and its 200-day moving average price is $26.36.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Thursday, August 8th. The technology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.09. The business had revenue of $647.10 million for the quarter, compared to analysts’ expectations of $636.46 million. Evolent Health had a negative net margin of 3.16% and a positive return on equity of 8.47%. The firm’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.06 earnings per share. Equities research analysts forecast that Evolent Health, Inc. will post 0.86 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Truist Financial reiterated a “buy” rating and set a $33.00 price target on shares of Evolent Health in a research report on Tuesday, August 27th. Stephens reiterated an “overweight” rating and set a $42.00 price target on shares of Evolent Health in a research report on Tuesday, July 30th. JMP Securities reduced their price target on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 price target on shares of Evolent Health in a research report on Monday, August 26th. Finally, JPMorgan Chase & Co. increased their price target on shares of Evolent Health from $36.00 to $45.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. One analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.40.

Insider Activity at Evolent Health

In related news, CEO Seth Blackley sold 187,904 shares of Evolent Health stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $5,637,120.00. Following the sale, the chief executive officer now owns 411,924 shares in the company, valued at $12,357,720. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Seth Blackley sold 187,904 shares of Evolent Health stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $5,637,120.00. Following the sale, the chief executive officer now owns 411,924 shares in the company, valued at $12,357,720. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO John Paul Johnson sold 44,693 shares of Evolent Health stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total transaction of $1,340,790.00. Following the completion of the sale, the chief financial officer now owns 171,207 shares in the company, valued at approximately $5,136,210. The disclosure for this sale can be found here. Insiders have sold a total of 307,291 shares of company stock worth $9,290,385 over the last quarter. Corporate insiders own 1.60% of the company’s stock.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.